Multiple Sclerosis
When to start, switch, and stop MS therapy: Real-world evidence counts
Updated EAN-ECTRIMS guideline on pharmacological MS treatment
Gut microbiota composition associated with disability worsening
Teriflunomide in children with MS: final results of TERIKIDS
Estimating brain age in MS: machine learning versus deep learning
Ofatumumab improves cognitive processing speed
Ublituximab versus teriflunomide in relapsing MS patients
Ketogenic diet may improve disability and quality of life
Favourable additional safety data for ofatumumab
Predicting new T2 lesions using a machine learning algorithm
Evobrutinib reduces volume of slowly expanding lesions
Sustained long-term efficacy and safety of satralizumab in NMOSD
WNT9B-gene variant associated with doubled relapse risk in MS
Melatonin associated with improved sleep quality in MS patients
“Expanded Disability Status Scale 0 is not normal”
Personality trait alterations in MS patients
Charcot Award 2021: Progressive MS, a personal perspective
Top score poster: Meta-analysis on the effect of DMTs
Cortical lesions predict disease progression and disability accumulation
Ocrelizumab shows long-term benefits in primary progressive MS
Changes in GABA-receptor binding among cognitively impaired MS patients
T2 lesions independently predict early conversion to SPMS
Natural killer-like CD8+ T cells as a reservoir of clonal cells related to MS activity
Early predictors of disability progression in paediatric-onset MS
High-sensitive biomarker detection in MS via novel ELISA assay
Cortical lesions predict cognitive impairment 20 years after MS diagnosis
Applicability of sNfL measurement in clinical practice
MRI more sensitive for disease activity than relapses in SPMS
ECTRIMS/EAN Clinical Guidelines on MS treatment: an update
Rituximab most effective initial MS therapy in Swedish real-world study
Ublituximab meets primary endpoint for relapsing MS
Dynamic scoring system aids decision to switch MS therapies early
Long-term suppression of MRI disease activity with ocrelizumab
Stopping DMT: when or if at all?
The role of astrocyte phenotypes in acute MS lesions
Promising results of intrathecal MSC-NTF cells in progressive MS
Preliminary data shows positive results of ATA188 for progressive MS
Evobrutinib reduces relapses and MRI lesion activity
Primary endpoint of opicinumab for relapsing MS not met in AFFINITY trial
Elezanumab did not outperform placebo in progressive and relapsing MS
Ibudilast reduced retinal atrophy in primary progressive MS
MS patients at risk of hampered immune response after vaccination
Immunotherapy in MS does not influence COVID-19 severity and mortality
Anti-CD20 antibodies associated with worse COVID-19 outcomes
ECTRIMS-EAN consensus on vaccination in MS patients
MRI and clinical features discriminate between MOGAD, AQP4-NMOSD, and RR-MS
ECTRIMS 2021 Highlights Podcast
Childhood infectious mononucleosis a risk factor for subsequent MS diagnosis
Typing behaviour to remotely monitor clinical MS status
Positive results from ublituximab versus teriflunomide
Alemtuzumab in treatment-naïve patients with aggressive MS
No higher early MS relapse frequency after stopping ponesimod
For MS, starting with highly effective disease-modifying treatment has clinical benefits
Dysmetabolism may drive MS progression
Plasma NfL and GFAP predict disability worsening in non-active secondary progressive MS
Ublituximab versus teriflunomide in relapsing MS
Predicting long-term prognosis in paediatric MS patients
Non-live COVID-19 vaccines likely safe, effective in MS patients, but immune response varies
Does fampridine improve upper limb function in MS?
Targeting cells in the CNS key to abrogate multiple sclerosis progression
Masitinib for progressive MS: Perspectives from Prof. Patrick Vermersch
Do anti-CD20 DMTs cause worse COVID-19 outcomes in MS?
MS Relapses “Belong to the Past”: Ofatumumab Safety Good
MS: EXCHANGE Trial Perspectives from Prof. Amit Bar-Or
No association between Ig levels and infection in ofatumumab-treated patients with relapsing MS
Defining phenotypes of MS-related cognitive impairment
First long-term efficacy data of a BTK inhibitor
Novel disease-specific scale confirms huge impact of fatigue
Progressive aerobic exercise improves fatigue
Reliable and convenient method to assess cognitive function in MS patients
Tackling unmet MS-related cognitive challenges
Real-world efficacy of ocrelizumab in MS patients
Superior effect of ponesimod versus teriflunomide on clinical disease activity and MRI-based outcomes
Similar demographics, clinical characteristics, and treatment patterns in German claims study
Amantadine, modafinil, methylphenidate not superior to placebo for MS fatigue
Age and EDSS are risk factors for severe COVID-19
Serum NfL as biomarker for suboptimal treatment response
Grey matter network measures predict disability and cognition
Management of progressive MS with approved DMT
Outcomes in patients on alemtuzumab with thyroid adverse events
Safety and efficacy of dimethyl fumarate: 13 years of follow-up
No new safety signals in ofatumumab open-label data
TERIKIDS trial extension of teriflunomide in paediatric MS
Teriflunomide improves satisfaction versus prior DMT regardless of age
Safety and efficacy of cladribine, glatiramer acetate, and more
Masitinib: a first-in-class TKI as treatment of progressive MS
Gold nanocrystals may improve brain metabolic profile
Cardiovascular risk factors may contribute to brain atrophy in MS patients
Amantadine, modafinil, and methylphenidate for MS-related fatigue
Genetic association studies in NMOSD needed
Eculizumab in NMOSD: the PREVENT study
Long-term safety of satralizumab consistent with double-blind periods
Imaging to evaluate remyelination and neuroprotection
MRI-based clustering of MS patients
Serum NfL predicts long-term clinical outcomes in MS
Epstein-Barr virus-targeted T-cell immunotherapy for progressive MS
High NEDA rates after 2 years of ocrelizumab
Two trials comparing relapsing MS treatments
Switching from natalizumab to moderate- versus high-efficacy DMT
Results of compounds in late stages of development
Alemtuzumab efficacy and safety data of over 9 years
Fampridine treatment results in routine clinical practice
Cognitive assessment in MS
Induction therapy over treatment escalation
The maternal perspective: when to stop/resume treatment and risks for progression
Challenges in diagnosing and treating progressive MS
Use of clinical registries in phase 4 of DMT
Treatment escalation over induction therapy
Foetal/child perspective: risks related to drug exposure and breastfeeding
Risk factors for conversion to secondary progressive MS
Genes, environment, and safety monitoring in using registries
Tool to measure quality of life in MS
Influence of age on disease progression
Patient awareness about family planning represents a major knowledge gap
Transplantation of autologous mesenchymal stem cells
Risk of hypogammaglobulinemia and rituximab
Novel ways to assess MS
Siponimod delays time to wheelchair
Determinants of outcomes for natalizumab-associated PML
Late-breaking: Role for CSF markers in autoimmune astrocytopathies
Exposure to DMTs reduces disability progression
Sustained reduction in disability progression with ocrelizumab
Serum immunoglobulin levels and risk of serious infections
Predicting long-term sustained disability progression
Treatment response scoring systems to assess long term prognosis
Late-breaking: Continuation of natalizumab or interruption during pregnancy
EAN guideline on palliative care
Late-breaking: Ofatumumab versus teriflunomide in relapsing MS
Late-breaking: Myelin-peptide coupled red blood cells
Targeted therapies for NMOSD in development
Treating MS from disease onset
Randomised and observational studies comparing treatments
Autologous haematopoietic stem cell transplantation
Immune tolerance by peptide-loaded tolerogenic dendritic cells
